|
Found 10 result(s) FROM 1963 pages containing the term 'Raynaud's'.
Wednesday Aug 19, 2009
Echo Urged to Rule Out PAH in High-Risk Lupus
Echocardiogram screening may be useful in identifying pulmonary arterial hypertension in high risk lupus patients...
Tuesday May 26, 2009
Little Science Behind Most Alternative Raynaud’s Remedies
Many patients with Raynaud's phenomenon try alternatives to conventional care, but a new analysis finds little data to support use of most such approaches...
Friday Dec 05, 2008
SSc Risk 60-Fold Higher in Raynaud's with SSc Antibodies, NCM Changes
Microvascular damage and systemic sclerosis (SSc)-specific antibodies can predict which Raynaud's phenomenon patients will progress to systemic sclerosis, and when...
Friday Jul 25, 2008
New High-Resolution Device Aids Finger MRI in Scleroderma
High-resolution magnetic resonance angiography (micro-MRA) can readily measure vascular disease of fingers in systemic sclerosis…
Tuesday Feb 26, 2008
ADHD Drugs Linked to Raynaud's Syndrome in Children
CNS stimulants used to treat ADHD have been linked to development of Raynaud's syndrome in children...
Wednesday Nov 14, 2007
New Topical Nitroglycerin for Raynaud's Phenomenon Reported at ACR
A new topical formulation of nitroglycerine that is not absorbed systemically significantly reduced symptoms in over 40% of patients with Raynaud's phenomenon...
Friday Jan 27, 2006
Phosphodiesterase Type 5 Inhibition Improves Raynaud's Disease
New research adds to evidence that because of their vasodilatory properties, phosphodiesterase type 5 inhibitors may be a useful therapeutic option for the treatment of Raynaud's disease... Caglayan E, et al. Arch Intern Med. 2006;166:231-233.
Tuesday Jun 28, 2005
Botox Injections Improve Symptoms in Patients With Raynaud's Phenomenon
Injections of botulinum toxin type A may accelerate the rewarming process by inhibiting vasoconstriction in patients with secondary Raynaud's phenomenon... Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Monday Dec 13, 2004
Clinical Decisions With COX-2s: Balancing GI Protection and Cardiovascular Risk
CIAOMed continues its series about the impact of the withdrawal of rofecoxib (VioxxR) from the worldwide market. The first installment (CIAOMed.org; November 9, 2004) discussed possible mechanisms of the cardiovascular (CV) risk observed with rofecoxib, and whether they apply to other cyclooxygenase-2 (COX-2) inhibitors. This second installment examines the impact of recent disclosures on changes in the selection of appropriate candidates for COX-2 inhibitors, on the reemergence of traditional antiinflammatory agents such as nonselective nonsteroidal antiinflammatory drugs (NSAIDs) for patients at risk for gastrointestinal complications, and on therapeutic decisions for those who require aspirin to maintain cardiovascular protection& Simon LS. Advanced Studies in Medicine. 2004;4:522-523.
Tuesday Nov 09, 2004
COX-2s, Pain Relief, and Cardiovascular Risk: Where Do We Go From Here?
In the first of a 3-part series, CIAOMed will examine possible underlying mechanisms that may be responsible for elevated cardiovascular risk in select COX-2 inhibitors and whether such explanations extend to all coxibs. Subsequent installments will examine how to manage patients in light of the new reports and the future of this frequently used drug class... Simon LS, Strand V. Cleve Clin J Med. 2004;71:849-856.
|
